A Phase I Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Duvelisib (Primary) ; Bortezomib; Romidepsin
- Indications T cell lymphoma
- Focus Adverse reactions
- 11 Dec 2017 According to a Verastem media release, results were presented at the American Society of Hematology (ASH) 2017 Annual Meeting.
- 11 Dec 2017 Results presented in a Verastem media release.
- 07 Nov 2017 Data from this trial will be presented at the American Society of Hematology 2017 Annual Meeting (ASH 2017), according to a Verastem media release.